- Home
- UWMC vs BBOT Comparison
UWMC vs BBOT Comparison
Compare UWMC & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$7.78
Company Overview
Basic Information| Metric | UWMC | BBOT |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | 9100 | 106 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.3M | 705.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UWMC | BBOT |
|---|---|---|
| Price | $2.21 | $7.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $6.13 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 23.5M | 307.2K |
| Earning Date | 05-06-2026 | 05-26-2026 |
| Dividend Yield | ★ 11.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.60 | N/A |
| P/E Ratio | $82.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $7.00 |
| 52 Week High | $7.14 | $14.87 |
Technical Indicators
Market Signals| Indicator | UWMC | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 19.87 | 40.72 |
| Support Level | N/A | $7.00 |
| Resistance Level | $4.01 | $9.50 |
| Average True Range (ATR) | 0.17 | 0.49 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 8.29 | 28.72 |
Price Performance
Historical Comparison UWMC
BBOT
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.